172900-95-7

Upstream product

• 28384-61-4 methacrylic acid N-(butyl)amide 
• 172900-84-4 2(S)-tert-butoxy-carbonyl-amino-4(S)-isopropyl-5-(p-tert-butyl-phenyl)-pentanal 
• 98-51-1 4-tert-butyltoluene 
• 172900-79-7 1-bromo-2(R)-isopropyl-3-(p-tert-butyl-phenyl)-propane 
• 172900-80-0 2(R)-isopropyl-3-(p-tert-butyl-phenyl)-propanol 
• 173335-96-1 2(S)-tert-butoxycarbonylamino-4(S)-isopropyl-5-(p-tert-butyl-phenyl)-pentanoic acid methyl ester 
• 18880-00-7 1-(bromomethyl)-4-(1,1-dimethylethyl)benzene 

Relevant academic research and scientific papers

METHODS OF TREATING ALZHEIMER'S DISEASE USING ARYL ALKANOIC ACID AMIDES

Disclosed are methods for treating Alzheimer’s disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of compounds of formula 1 (1) wherein the variables R1-R8 and X are defined herein.

Design and synthesis of novel 2,7-dialkyl substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides as in vitro potent peptidomimetic inhibitors of human renin

Novel low-molecular weight transition-state peptidomimetic renin inhibitors characterized by an all-carbon 8-phenyl substituted octanecarboxamide skeleton have been discovered based on a topographical design approach. The in vitro most potent inhibitors 21, 25 and 26 incorporating a strong H-bond acceptor group linked to the benzyl spacer of the (P3-P1)-unit had IC50s in the low nanomolar range against human renin.